171 related articles for article (PubMed ID: 23679284)
1. Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.
Su A; Zhang J; Pan ZH; Zhou QM; Lv X
Asian Pac J Cancer Prev; 2013; 14(3):1841-6. PubMed ID: 23679284
[TBL] [Abstract][Full Text] [Related]
2. Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Suprasert P; Cheewakriangkrai C; Manopunya M
Asian Pac J Cancer Prev; 2012; 13(2):517-20. PubMed ID: 22524817
[TBL] [Abstract][Full Text] [Related]
3. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Konstantinopoulos PA; Cheng SC; Wahner Hendrickson AE; Penson RT; Schumer ST; Doyle LA; Lee EK; Kohn EC; Duska LR; Crispens MA; Olawaiye AB; Winer IS; Barroilhet LM; Fu S; McHale MT; Schilder RJ; Färkkilä A; Chowdhury D; Curtis J; Quinn RS; Bowes B; D'Andrea AD; Shapiro GI; Matulonis UA
Lancet Oncol; 2020 Jul; 21(7):957-968. PubMed ID: 32553118
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Li Y; Yang Y; Shang YM; Zheng H
Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
6. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
7. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
8. Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.
Safra T; Ron I; Boaz M; Brenner J; Grisaru D; Inbar M; Hayat H; Menczer J; Golan A; Levy T
Acta Oncol; 2006; 45(4):463-8. PubMed ID: 16760183
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of permanent iodine-125 seed implants and gemcitabine chemotherapy in patients with platinum- resistant recurrent ovarian carcinoma.
Yang H; Liu YH; Xu L; Liu LH
Asian Pac J Cancer Prev; 2014; 15(20):9009-13. PubMed ID: 25374244
[TBL] [Abstract][Full Text] [Related]
11. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.
Kodaz H; Hacibekiroglu I; Turkmen E; Erdogan B; Elpen C; Uzunoglu S; Cicin I
Tumori; 2015; 101(1):36-40. PubMed ID: 25702671
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K; Gounaris I; Basu B; Freeman S; Moyle P; Hosking K; Iddawela M; Jimenez-Linan M; Abraham J; Brenton J; Hatcher H; Earl H; Parkinson C
Int J Gynecol Cancer; 2015 Jul; 25(6):977-84. PubMed ID: 25962114
[TBL] [Abstract][Full Text] [Related]
13. [Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Chu P; Lu CH; Sheng XG; Zhou CX; Li DP; DU XL; Liu NF
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):808-12. PubMed ID: 21211276
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
Yoshino K; Hiramatsu K; Enomoto T; Fujita M; Ueda Y; Kimura T; Kobayashi E; Kiyohara Y; Tsutsui T; Kimura T
Anticancer Res; 2012 Sep; 32(9):4029-33. PubMed ID: 22993355
[TBL] [Abstract][Full Text] [Related]
15. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
[TBL] [Abstract][Full Text] [Related]
16. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Jansaka N; Suprasert P
Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
19. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
20. Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Takasaki K; Miyamoto M; Takano M; Soyama H; Aoyama T; Matsuura H; Kato K; Sakamoto T; Kuwahara M; Iwahashi H; Ishibashi H; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 May; 81(5):809-814. PubMed ID: 29500481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
